Medtronic plc
HealthcareNYSE:MDT · New York Stock Exchange
-$0.05 today
Vol 3.43M · Avg 9.86M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
0.0%
avg 7.3%
ROIC
0.0%
avg 4.9%
ROA
0.0%
avg 4.0%
Analysis
ROE is currently the strongest return metric at 0.0% versus its period average of 7.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Geoffrey Straub Martha | Chairman of the Board & Chief Executive Officer | $3.81M | — | 56 | $301,163.00 | 0.02% |
Brett A. Wall | Executive Officer | $1.86M | — | 60 | $82,183.00 | <0.01% |
Michelle Quinn | Executive Vice President, General Counsel & Secretary | $985,574.00 | — | 57 | $38,336.00 | <0.01% |
Thierry Pieton | Executive Vice President & Chief Financial Officer | $421,766.00 | — | 56 | $37,574.00 | <0.01% |
Laura Mauri | Senior Vice President and Chief Scientific & Medical Officer | — | — | 56 | — | — |
Alex Gu | Senior VP & President of Greater China Region | — | — | — | — | — |
Jason Weidman | Senior VP and President of Coronary & Renal Denervation business | — | — | — | — | — |
Mark Ploof | Senior Vice President of Global Operations and Business Services | — | — | — | — | — |
Matthew Walter | Senior Vice President of Human Resources, IT and Global Communications & Corporate Marketing | — | — | 47 | $38,689.00 | <0.01% |
Rogerio Branco | SVP & Chief Operations and Supply Chain Officer | — | — | — | — | — |
Denise L. Blomquist | Vice President, Global Controller & Chief Accounting Officer | — | — | — | $14,737.00 | <0.01% |
Ingrid Goldberg | Vice President & Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$462,750.00
Sells
16
$9.32M
Net Sentiment
$8.85M
Net selling
Most Active
KIIL HARRY SKIP
9 transactions
1–10 of 18
Analysis
Insiders reported 2 buys worth $462,750.00 and 16 sells worth $9.32M over the last 12 months. That adds up to net selling of $8.85M. KIIL HARRY SKIP was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -9.7% | +8.3% (15yr)2 analysts |
| Revenue | N/A | N/A | +20.2% | +3.2% (15yr)5 analysts |
| Net Income | N/A | N/A | +0.7% | +7.6% (15yr)5 analysts |
| EBIT | N/A | N/A | +6.8% | +4.0% (15yr)5 analysts |
Analysis
Recent growth has been strongest in Revenue at +20.2% over three years. Forward estimates point to EPS at +8.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$129.95B
Stryker Corporation
NYSE:SYK
$120.03B
Bristol-Myers Squibb Company
NYSE:BMY
$116.51B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.66B
GSK plc
NYSE:GSK
$106.56B
Sanofi
NASDAQ:SNY
$106.46B
McKesson Corporation
NYSE:MCK
$94.83B
HCA Healthcare, Inc.
NYSE:HCA
$85.78B
Boston Scientific Corporation
NYSE:BSX
$69.84B
Edwards Lifesciences Corporation
NYSE:EW
$48.81B
Who manages MDT?
Medtronic plc (MDT) lists 12 active executives. The top listed executive is Thierry Pieton, Executive Vice President & Chief Financial Officer.
Are MDT insiders buying or selling?
Recent insider activity shows net buying of $37.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.